BDNF and colorectal carcinoma: Compared with MSI-H/dMMR status and PD-L1 expression, changes in serum IL-1RA and BDNF levels were superior in identifying patients with metastatic ESCC or CRC and GC, respectively, who would respond to ICB therapy.